Featured Stories

I have worked in cardiology for over 30 years, in hospitals, clinical societies and most recently at Boston Scientific. In that time, I have seen first-hand the evolution of treating arrhythmias...

Our commitment to patient health goes beyond medical innovation. It recognises the connection between environmental and human well-being. That’s why we’re working to reduce our carbon...

People with advanced renal cell carcinoma (RCC), the most common type of kidney cancer, could benefit from a minimally invasive therapy called thermal ablation, according to new guidelines from...

In regions where traditional healthcare systems have difficulty reaching rural or underserved populations, women face significant barriers to accessing healthcare. From limited screening services...

For 69-year-old Eulogio, painting in his studio and taking walks have long been part of his routine. Nearly 25 years ago, he began experiencing prostate-related symptoms..

Marking the first anniversary of the National Institute for Health and Care Excellence (NICE)’s final diagnostic guidance recommending two technologies for the remote monitoring of heart...

When David Stanley discovered he had kidney cancer, the news came on a day meant for celebration. Yet what followed was not a story of prolonged illness, but one of swift diagnosis and a rapid...

At Boston Scientific, we are working to confront climate change with a goal of achieving net-zero GHG emissions by 2050. In 2024, we made noteworthy progress by achieving 100% renewable electricity.

Benign prostatic hyperplasia (BPH) is a rapidly growing urological concern driven by a global aging population. With healthcare systems under strain due to increased demand, resource limitations,...

This year, TheraSphere™ Y-90 Glass Microspheres celebrates its 20th anniversary. Since its launch, TheraSphere has changed the way liver cancers are treated, helping more than 100,000 patients worldwide and over 30, 000 patients in the EMEA region.